Wells Fargo & Co reissued their positive rating on shares of Illumina (NASDAQ:ILMN) in a research report report published on Tuesday morning, The Fly reports. Wells Fargo & Co currently has a $260.00 price objective on the life sciences company’s stock, up from their previous price objective of $250.00.
ILMN has been the topic of several other research reports. Barclays increased their target price on Illumina from $150.00 to $185.00 and gave the company an equal weight rating in a research report on Wednesday, October 25th. Zacks Investment Research raised Illumina from a hold rating to a buy rating and set a $229.00 target price on the stock in a research report on Friday, October 27th. Canaccord Genuity reaffirmed a buy rating and set a $230.00 target price (up previously from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Piper Jaffray Companies reaffirmed an overweight rating and set a $226.00 target price (up previously from $202.00) on shares of Illumina in a research report on Monday, October 9th. Finally, Janney Montgomery Scott raised Illumina from a sell rating to a neutral rating in a research report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $214.38.
Shares of Illumina (ILMN) traded down $2.55 during midday trading on Tuesday, reaching $240.04. The company’s stock had a trading volume of 810,000 shares, compared to its average volume of 1,194,313. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The company has a market cap of $35,800.00, a PE ratio of 45.29, a PEG ratio of 3.13 and a beta of 0.79. Illumina has a 1-year low of $156.50 and a 1-year high of $245.74.
In related news, EVP Omead Ostadan sold 3,540 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $226.91, for a total value of $803,261.40. Following the completion of the transaction, the executive vice president now owns 26,827 shares in the company, valued at approximately $6,087,314.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $210.43, for a total value of $4,208,600.00. Following the completion of the transaction, the director now owns 539,176 shares of the company’s stock, valued at approximately $113,458,805.68. The disclosure for this sale can be found here. Insiders sold a total of 137,671 shares of company stock valued at $29,485,768 in the last three months. Insiders own 0.89% of the company’s stock.
A number of hedge funds have recently modified their holdings of ILMN. Vanguard Group Inc. raised its stake in shares of Illumina by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after buying an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Illumina by 3.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock valued at $500,416,000 after buying an additional 76,452 shares during the last quarter. Capital World Investors raised its stake in shares of Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC purchased a new position in shares of Illumina during the 2nd quarter valued at about $211,584,000. Institutional investors own 91.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2018/01/12/wells-fargo-co-reiterates-positive-rating-for-illumina-ilmn.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
What are top analysts saying about Illumina? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina and related companies.